An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?

Sarah Barrett, Gerard Hanna, Laure Marignol

Research output: Contribution to journalReview article

1 Citation (Scopus)
75 Downloads (Pure)

Abstract

Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20%. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria. 19 relevant studies were identified ranging from prospective clinical trials to mathematically modelled concept studies. Heterogeneity existed between all clinical studies. Nine heterogeneous publications proposed methodology to adapt the dose prescription to the individual patient. A number of encouraging strategies have been identified but fall short of the evidence level required to influence clinical practice.
Original languageEnglish
Pages (from-to)1-14
JournalRadiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Early online date13 Jun 2018
DOIs
Publication statusEarly online date - 13 Jun 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Prescriptions
Radiotherapy
Standard of Care
Publications
Randomized Controlled Trials
Clinical Trials
Survival

Keywords

  • Radiotherapy
  • Personalised Medicine
  • Lung Cancer

Cite this

@article{65adb6e0342f4c05b5ce2bb0db6882af,
title = "An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?",
abstract = "Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20{\%}. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria. 19 relevant studies were identified ranging from prospective clinical trials to mathematically modelled concept studies. Heterogeneity existed between all clinical studies. Nine heterogeneous publications proposed methodology to adapt the dose prescription to the individual patient. A number of encouraging strategies have been identified but fall short of the evidence level required to influence clinical practice.",
keywords = "Radiotherapy, Personalised Medicine, Lung Cancer",
author = "Sarah Barrett and Gerard Hanna and Laure Marignol",
year = "2018",
month = "6",
day = "13",
doi = "10.1016/j.radonc.2018.05.029.",
language = "English",
pages = "1--14",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier",

}

TY - JOUR

T1 - An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?

AU - Barrett, Sarah

AU - Hanna, Gerard

AU - Marignol, Laure

PY - 2018/6/13

Y1 - 2018/6/13

N2 - Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20%. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria. 19 relevant studies were identified ranging from prospective clinical trials to mathematically modelled concept studies. Heterogeneity existed between all clinical studies. Nine heterogeneous publications proposed methodology to adapt the dose prescription to the individual patient. A number of encouraging strategies have been identified but fall short of the evidence level required to influence clinical practice.

AB - Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20%. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria. 19 relevant studies were identified ranging from prospective clinical trials to mathematically modelled concept studies. Heterogeneity existed between all clinical studies. Nine heterogeneous publications proposed methodology to adapt the dose prescription to the individual patient. A number of encouraging strategies have been identified but fall short of the evidence level required to influence clinical practice.

KW - Radiotherapy

KW - Personalised Medicine

KW - Lung Cancer

U2 - 10.1016/j.radonc.2018.05.029.

DO - 10.1016/j.radonc.2018.05.029.

M3 - Review article

SP - 1

EP - 14

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -